FDA approves Lilly's Foundayo, the only GLP-1 pill with no food or water restrictions
The first oral GLP-1 you can take any time of day, with no food or water timing rules. A new option for adults with obesity or overweight and a related condition.
The FDA has approved orforglipron, sold under the brand name Foundayo, for chronic weight management in adults with obesity or overweight and at least one weight-related condition. It is Eli Lilly’s first oral GLP-1 and the first in the class with no food or water timing rules.
Why this one is different
Until now the only GLP-1 pill was oral semaglutide, which has to be taken on an empty stomach in the morning with a small sip of water, then nothing else by mouth for 30 minutes. Foundayo is a small molecule rather than a peptide, so it can be taken any time of day, with or without food, swallowed whole. For people who want a GLP-1 without weekly injections, that removes the biggest everyday friction the pill route carried.
What the trials showed
In Lilly’s ATTAIN Phase 3 program, adults taking orforglipron lost about 12 percent of their body weight on average at the highest dose, over roughly a year and a half. That sits below the injectable GLP-1s in cross-trial comparisons, with tirzepatide around 21 percent and semaglutide around 15 percent, but well above diet and exercise alone. Our expected weight loss page breaks out the numbers by medication, and the dosing schedule page covers how the dose steps up.
What it means for pricing
A pill that is easier to manufacture and ship than an injectable pen could matter for price competition across the whole category. We are tracking which telehealth providers add Foundayo to their offerings and what they charge as listings appear, the same way we track every other medication on the comparison page.
As always, whether any GLP-1 is right for you is a decision for you and a licensed prescriber.